Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04582474
Other study ID # FE008
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 10, 2020
Est. completion date December 2020

Study information

Verified date September 2020
Source Foundation for Innovative New Diagnostics, Switzerland
Contact Brice W Bicaba, MD
Phone +22670264393
Email bicaba_brico@yahoo.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Integrated Management of Childhood Illness (IMCI) guideline has been implemented in Burkina Faso and is used across primary health facilities to assess children under the age of 5 years. A part from a rapid diagnostic test (RDT) for malaria, no other point of care in vitro diagnostic tests are widely used to improve disease diagnosis and inform treatment decisions. Dengue fever has been reported in Burkina Faso since 1925 and the recent epidemics in 2016 and 2017 have prompted the government to validate and deploy a clinical management algorithm for Dengue and a case reporting process to support surveillance for a targeted response.

The organisation Terre des hommes has digitalised IMCI and implemented the module through its Integrated electronic Diagnosis Approach (IeDA) programme across primary health care centers (PHCs) in the country with proven impact on clinical care and proven reduction in antibiotic prescriptions. Many recognize the need to update the IMCI guideline with current evidence. However this is challenging and may require large clinical trials. The advantage of electronic clinical decision support systems is plural: they improve quality of care through increased adherence and feedback information to the system; they strengthen surveillance systems by connecting relevant patient related data and provide geo-tagged coordinates for targeted responses; and they can become evidence-adaptive.

An electronic module of the Burkina Faso Dengue clinical management guideline accompanied with dengue rapid diagnostic tests has the potential to improve the diagnosis of non-malaria fevers in particular during "dengue seasons" and improve the efficiency of surveillance for this disease.

In this study, the investigators aim to assess the usability and the performance of the dengue module for patient management in primary health care facilities.


Recruitment information / eligibility

Status Recruiting
Enrollment 335
Est. completion date December 2020
Est. primary completion date November 2020
Accepts healthy volunteers No
Gender All
Age group 6 Months and older
Eligibility Inclusion Criteria:

- Older than 6 month

- Presentation with fever (axillary temperature = 37,5°C) or history of fever for 2-7 days without localizing signs of another pathology such as malaria diagnosed by RDT

- Malaria diagnosis: negative malaria RDT performed at the the study site by a nurse as part of the routine consultation, or a positive malaria RDT with antimalarial treatment failure

Exclusion Criteria:

- Neonates (0-2 months) and children = 6 month for operational reasons such as difficulties with blood draw

- Patients with severe disease requiring urgent care

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Dengue module and rapid diagnostic tests
Digital platform providing clinical decision support for Dengue, Dengue rapid diagnostic tests and training will be deployed at study sites for Dengue screening, diagnosis, case management as well as reporting to surveillance system following local guidelines

Locations

Country Name City State
Burkina Faso Centre de Santé et de Promotion Sociale (Sandogo) Ouagadougou District Boulmiougou
Burkina Faso Centre de Santé et de Promotion Sociale (Secteur 16) Ouagadougou District Boulmiougou

Sponsors (3)

Lead Sponsor Collaborator
Foundation for Innovative New Diagnostics, Switzerland Ministry of Health, Burkina Faso, Terre des hommes, Burkina Faso & Switzerland

Country where clinical trial is conducted

Burkina Faso, 

Outcome

Type Measure Description Time frame Safety issue
Primary Point estimates of the percentage of dengue consultations performed using the dengue module, with 95% confidence intervals This outcome will be evaluated by reporting the ratio of dengue consultations performed using the dengue module over the total number of consultations, together with a 95% confidence interval based on Wilson's score method. 4 months
Primary Evaluation of the adherence to the different steps of the module This outcome will be evaluated by the percentage ratio of dengue module steps adhered by patients over the total number of patients at each step. 4 months
Secondary Estimate of the operational characteristic, Efficacy, of the dengue module: percentage of forms emitted from the module received in the surveillance system 4 months
Secondary Estimate of the operational characteristic, Timeliness, of the dengue module: percentage of forms that are received by the surveillance system on time, as defined by the national surveillance system. 4 months
Secondary Estimate of operational characteristic, Completeness, of the dengue module: percentage of fields that are completed. 4 months
Secondary Positive predictive value of dengue rapid diagnostic test Polymerase chain reaction results will be used as the reference test. 4 months
See also
  Status Clinical Trial Phase
Completed NCT05321264 - Educational Intervention to Promote Control Behaviors and Prevention of Dengue N/A
Completed NCT01436396 - Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers Phase 3
Completed NCT01391819 - Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children N/A
Completed NCT03641339 - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans N/A
Completed NCT02833584 - Safety of Paracetamol as Antipyretic in Treatment of Dengue Infection in Adults N/A
Completed NCT02433652 - Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2 Phase 1
Enrolling by invitation NCT02016027 - Pharmacological Effect of Carica Papaya Leaves Mother Tincture in Healthy Individuals Blood Parameter Phase 1
Completed NCT01477671 - Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children N/A
Recruiting NCT00377754 - Prospective Study of Infant Dengue N/A
Recruiting NCT05919277 - A Dengue Sero-prevalence Study in the Metropolitan Area of Buenos Aires
Completed NCT01983553 - Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
Completed NCT03803618 - Dengue Effectiveness Study in the Philippines
Active, not recruiting NCT05967455 - Homologous Re-infection With Dengue 1 or Dengue 3 Phase 1
Completed NCT03631719 - Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
Recruiting NCT02606019 - The Use of Biomarkers in Predicting Dengue Outcome N/A
Completed NCT02372175 - Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain Phase 1
Active, not recruiting NCT01696422 - Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine Phase 2
Completed NCT00993447 - Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America Phase 2
Completed NCT00375726 - Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults Phase 1
Completed NCT05153018 - Population Immunity AgaiNst mosquitO-borne Diseases in Vanuatu N/A